Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era

The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentia...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutics and clinical risk management 2020-01, Vol.16, p.759-767
Main Authors: Hamdy, Sherif M, Abdel-Naseer, Maged, Shehata, Hatem S, Shalaby, Nevin M, Hassan, Amr, Elmazny, Alaa, Shaker, Ehab, Nada, Mona A F, Ahmed, Sandra M, Hegazy, Mohamed I, Mourad, Husam S, Abdelalim, Ahmed, Magdy, Rehab, Othman, Alshimaa S, Mekkawy, Doaa A, Kishk, Nirmeen A
Format: Article
Language:English
Subjects:
Antibodies
Blood tests
Coronaviruses
COVID-19
covid19
Cytokines
Drug dosages
Immunoglobulins
Infections
Laboratories
Lymphocytes
neuromyelitis optica spectrum disorder
pandemic
Pandemics
Pathophysiology
Patients
Review
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/TCRM.S261753